Recent Finacing
Recent Raise
CymaBay Therapeutics develops seladelpar for primary biliary cholangitis, conducting a 52-week global Phase 3 randomized trial of about 180 patients with ongoing dosing and a planned open-label extension.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at CymaBay Therapeutics.
